EUVIMEDOdkrijte EUVIMED
Crossref

Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios

Kelsey Coffman iD, Neha Patel iD, Felicia Bartlett, Jessica Newman, Shikha Patel iD, Taylor Sprague, Nikhil Rao, Erika Andrade, Michael J Casey, Vinayak Rohan, Derek DuBay, David Taber iD

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14944 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Kelsey Coffman and 11 co-authors. Institution: Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA. Major MEDLINE topics: Tacrolimus, Diabetes Mellitus. 28 references.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Diabetes (DM) is a common comorbidity in transplant patients with known effects on gastrointestinal (GI) motility and absorption; however, DM's impact on immediate release (IR) tacrolimus to LCP‐tacrolimus (LCP) conversion ratios has not been studied. This multivariable analysis of a retrospective longitudinal cohort study included kidney transplant recipients converted from IR to LCP between 2019 and 2020. The primary outcome was IR to LCP conversion ratio based on DM status. Other outcomes included tacrolimus variability, rejection, graft loss, and death. Of the 292 patients included, 172 patients had DM and 120 did not. The IR:LCP conversion ratio was significantly higher with DM (67.5% ± 21.1% no DM vs. 79.8% ± 28.7% in DM; P < .001). In multivariable modeling, DM was the only variable significantly and independently associated with IR:LCP conversion ratios. No difference was observed in rejection rates. Graft (97.5% no DM vs. 92.4% in DM; P = .062) and patient survival (100% no DM vs. 94.8% in DM; P = .011) were lower with DM. The presence of DM significantly increased the IR:LCP conversion ratio by 13%–14%, compared to patients without DM. On multivariable analysis, DM was the only significant predictor of conversion ratios, potentially related to GI motility or absorption differences.

Subjects

MeSH terms (MEDLINE)

TacrolimusDiabetes MellitusHumansImmunosuppressive AgentsRetrospective StudiesLongitudinal StudiesDelayed-Action PreparationsGraft Rejection

Author keywords

diabetesimmunosuppressiontacrolimus

Substances

TacrolimusImmunosuppressive AgentsDelayed-Action Preparations

Authors and institutions

  • Department of Pharmacy Services, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Pharmacy, Ralph H Johnson VAMC, Charleston, South Carolina, USA.

ORCID profiles: Kelsey Coffman, Neha Patel, Shikha Patel, David Taber

Cite

APA

Coffman, K., Patel, N., Bartlett, F., Newman, J., Patel, S., Sprague, T., Rao, N., Andrade, E., Casey, M. J., Rohan, V., DuBay, D., & Taber, D. (2023). Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios. Clinical Transplantation. https://doi.org/10.1111/ctr.14944

Vancouver

Coffman K, Patel N, Bartlett F, Newman J, Patel S, Sprague T, et al. Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios. Clinical Transplantation. 2023. doi:10.1111/ctr.14944

BibTeX
@article{Coffman2023,
  author = {Coffman, Kelsey and Patel, Neha and Bartlett, Felicia and Newman, Jessica and Patel, Shikha and Sprague, Taylor and Rao, Nikhil and Andrade, Erika and Casey, Michael J and Rohan, Vinayak and DuBay, Derek and Taber, David},
  title = {Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14944}
}
Start for free →